Women in the United Kingdom are experiencing renewed supply disruptions affecting specific hormone replacement therapy medications used to manage menopause symptoms. According to a notification from the Department of Health and Social Care issued this week, FemSeven Conti patches are currently unavailable and expected to remain out of stock until late November. Additionally, various Estradot patches face shortages that are anticipated to continue through January.
The affected products represent a significant portion of HRT options available to patients. FemSeven Conti patches contain estradiol and levonorgestrel, while Estradot patches contain estradiol. These medications are among several formulations—including gels, sprays, creams, and intrauterine systems—used to replace hormone levels during menopause. Data from the NHS Business Services Authority indicates that nearly 2 million women aged 40 and above in England received HRT prescriptions during 2025-26.
Supply challenges are not new to the HRT market. According to the NHSBSA, shortages of certain products began in December 2024, with Estradot experiencing particularly prolonged disruptions. Industry representatives have expressed concern about the recurring nature of these issues. Experts note that some HRT products are specialized formulations that cannot always be readily substituted.
Healthcare professionals have identified alternative options for affected patients. For those unable to access FemSeven Conti, alternatives include Evorel Conti and specific Estradot variants, which contain the same estradiol dose but use different synthetic progestogens and require twice-weekly application rather than weekly dosing. Similar alternatives exist for Estradot shortages. Consultants emphasize that maintaining the same estradiol dose is the primary concern, as progestogens serve to protect the uterine lining rather than directly address menopause symptoms.
Patients experiencing disruptions are advised to consult their clinician rather than independently adjusting their treatment regimen. Experts caution against extending patch wear duration, dividing patches, or obtaining medications from other sources. Industry leaders have called for government intervention, specifically requesting the establishment of a taskforce to address supply chain vulnerabilities comprehensively.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI